189 related articles for article (PubMed ID: 23326490)
1. The cancer stem cell marker CD133 interacts with plakoglobin and controls desmoglein-2 protein levels.
Koyama-Nasu R; Takahashi R; Yanagida S; Nasu-Nishimura Y; Oyama M; Kozuka-Hata H; Haruta R; Manabe E; Hoshino-Okubo A; Omi H; Yanaihara N; Okamoto A; Tanaka T; Akiyama T
PLoS One; 2013; 8(1):e53710. PubMed ID: 23326490
[TBL] [Abstract][Full Text] [Related]
2. CD133: molecule of the moment.
Mizrak D; Brittan M; Alison M
J Pathol; 2008 Jan; 214(1):3-9. PubMed ID: 18067118
[TBL] [Abstract][Full Text] [Related]
3. Polarized cell migration induces cancer type-specific CD133/integrin/Src/Akt/GSK3β/β-catenin signaling required for maintenance of cancer stem cell properties.
Su YJ; Lin WH; Chang YW; Wei KC; Liang CL; Chen SC; Lee JL
Oncotarget; 2015 Nov; 6(35):38029-45. PubMed ID: 26515729
[TBL] [Abstract][Full Text] [Related]
4. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells.
Bidlingmaier S; Zhu X; Liu B
J Mol Med (Berl); 2008 Sep; 86(9):1025-32. PubMed ID: 18535813
[TBL] [Abstract][Full Text] [Related]
5. CD133 induces tumour-initiating properties in HEK293 cells.
Canis M; Lechner A; Mack B; Zengel P; Laubender RP; Koehler U; Heissmeyer V; Gires O
Tumour Biol; 2013 Feb; 34(1):437-43. PubMed ID: 23150174
[TBL] [Abstract][Full Text] [Related]
6. CD133+ melanoma subpopulations contribute to perivascular niche morphogenesis and tumorigenicity through vasculogenic mimicry.
Lai CY; Schwartz BE; Hsu MY
Cancer Res; 2012 Oct; 72(19):5111-8. PubMed ID: 22865455
[TBL] [Abstract][Full Text] [Related]
7. Proteomic profiling of tumor-initiating cells in HT-29 human colorectal cancer cells.
Lee HN; Park SH; Lee EK; Bernardo R; Kim CW
Biochem Biophys Res Commun; 2012 Oct; 427(1):171-7. PubMed ID: 22995320
[TBL] [Abstract][Full Text] [Related]
8. CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme.
Choy W; Nagasawa DT; Trang A; Thill K; Spasic M; Yang I
Neurosurg Clin N Am; 2012 Jul; 23(3):391-405. PubMed ID: 22748652
[TBL] [Abstract][Full Text] [Related]
9. CD133 as a marker for cancer stem cells: progresses and concerns.
Wu Y; Wu PY
Stem Cells Dev; 2009 Oct; 18(8):1127-34. PubMed ID: 19409053
[TBL] [Abstract][Full Text] [Related]
10. Cell-surface Vimentin: A mislocalized protein for isolating csVimentin(+) CD133(-) novel stem-like hepatocellular carcinoma cells expressing EMT markers.
Mitra A; Satelli A; Xia X; Cutrera J; Mishra L; Li S
Int J Cancer; 2015 Jul; 137(2):491-6. PubMed ID: 25487874
[TBL] [Abstract][Full Text] [Related]
11. In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines.
Zito G; Richiusa P; Bommarito A; Carissimi E; Russo L; Coppola A; Zerilli M; Rodolico V; Criscimanna A; Amato M; Pizzolanti G; Galluzzo A; Giordano C
PLoS One; 2008; 3(10):e3544. PubMed ID: 18958156
[TBL] [Abstract][Full Text] [Related]
12. The stem cell marker CD133 associates with enhanced colony formation and cell motility in colorectal cancer.
Elsaba TM; Martinez-Pomares L; Robins AR; Crook S; Seth R; Jackson D; McCart A; Silver AR; Tomlinson IP; Ilyas M
PLoS One; 2010 May; 5(5):e10714. PubMed ID: 20502714
[TBL] [Abstract][Full Text] [Related]
13. Cancer stem-like cells in human prostate carcinoma cells DU145: the seeds of the cell line?
Wei C; Guomin W; Yujun L; Ruizhe Q
Cancer Biol Ther; 2007 May; 6(5):763-8. PubMed ID: 17592251
[TBL] [Abstract][Full Text] [Related]
14. CD133(+) gallbladder carcinoma cells exhibit self-renewal ability and tumorigenicity.
Shi CJ; Gao J; Wang M; Wang X; Tian R; Zhu F; Shen M; Qin RY
World J Gastroenterol; 2011 Jun; 17(24):2965-71. PubMed ID: 21734809
[TBL] [Abstract][Full Text] [Related]
15. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment.
Bertolini G; Roz L; Perego P; Tortoreto M; Fontanella E; Gatti L; Pratesi G; Fabbri A; Andriani F; Tinelli S; Roz E; Caserini R; Lo Vullo S; Camerini T; Mariani L; Delia D; Calabrò E; Pastorino U; Sozzi G
Proc Natl Acad Sci U S A; 2009 Sep; 106(38):16281-6. PubMed ID: 19805294
[TBL] [Abstract][Full Text] [Related]
16. CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor).
Choijamts B; Jimi S; Kondo T; Naganuma Y; Matsumoto T; Kuroki M; Iwasaki H; Emoto M
Stem Cells; 2011 Oct; 29(10):1485-95. PubMed ID: 21919130
[TBL] [Abstract][Full Text] [Related]
17. CD133/Src axis mediates tumor initiating property and epithelial-mesenchymal transition of head and neck cancer.
Chen YS; Wu MJ; Huang CY; Lin SC; Chuang TH; Yu CC; Lo JF
PLoS One; 2011; 6(11):e28053. PubMed ID: 22140506
[TBL] [Abstract][Full Text] [Related]
18. Protein CD133 as a tumor stem cell marker.
Grabovenko FI; Kisil OV; Pavlova GV; Zvereva ME
Zh Vopr Neirokhir Im N N Burdenko; 2022; 86(6):113-120. PubMed ID: 36534632
[TBL] [Abstract][Full Text] [Related]
19. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
Le H; Zeng F; Xu L; Liu X; Huang Y
Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
[TBL] [Abstract][Full Text] [Related]
20. In vivo 5FU-exposed human medullary thyroid carcinoma cells contain a chemoresistant CD133+ tumor-initiating cell subset.
Kucerova L; Feketeova L; Kozovska Z; Poturnajova M; Matuskova M; Nencka R; Babal P
Thyroid; 2014 Mar; 24(3):520-32. PubMed ID: 24073856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
